Sex-based differences in the lung immune microenvironment are associated with an increased risk of lung cancer in women
- PMID: 39019152
- PMCID: PMC11733063
- DOI: 10.1016/j.jtcvs.2024.07.017
Sex-based differences in the lung immune microenvironment are associated with an increased risk of lung cancer in women
Abstract
Objective: Lung cancer remains a major cause of mortality worldwide, necessitating further understanding of carcinogenesis and its driving factors, including those influenced by sex-dependent variables. We hypothesized that sex-specific lung immune composition may contribute to a greater risk of lung cancer in women.
Methods: Data from 1056 lung cancer screenings were examined for an association between sex and lung cancer risk using time-to-event analyses. Immune profiling by flow cytometry was performed on male and female lungs of 3 independent mouse models: nontumor bearing, KRAS mutated, and urethane-exposed carcinogenic. A comparable analysis was performed on human bronchoalveolar lavage samples (n = 81) from patients with lung cancer.
Results: Of the high-risk screening cohort examined, 60 patients (5.7%) developed lung cancer during median follow-up of 43.4 months. Multivariable stepwise modeling retained female sex (hazard ratio, 1.56; P < .01) and age (P < .01) as prognostic indicators for lung cancer development. Female lung immune profiles in patients included T-cell phenotypes consistent with exhaustion (eg, higher proportions of PD-1+ Ki67-; P = .02), an expanded pool of regulatory T-cells (P = .03), reduced effector T-cell frequencies (P = .008), and enhancements in suppressive myeloid populations (P = .02) versus male patients, and this is recapitulated in mouse studies.
Conclusions: Female smokers display higher risk for lung cancer. In murine models and humans, female sex is associated with robust immunosuppression within the lung. Further examination of this link will be important in developing immune-based approaches to lung cancer interception and their optimal application across the sexes.
Keywords: carcinogenesis; immune profile; lung cancer; sex differences.
Copyright © 2024 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Statement Dr Yendamuri serves as a scientific advisory board member for Karkinos Healthcare and reports grant funding from Lumeda Inc. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Similar articles
-
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.Cancer Lett. 2020 Feb 1;470:95-105. doi: 10.1016/j.canlet.2019.10.027. Epub 2019 Oct 20. Cancer Lett. 2020. PMID: 31644929
-
The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.J Thorac Cardiovasc Surg. 2022 Jan;163(1):e73-e85. doi: 10.1016/j.jtcvs.2020.05.097. Epub 2020 Jun 21. J Thorac Cardiovasc Surg. 2022. PMID: 32739163
-
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy.Int J Mol Sci. 2021 Dec 22;23(1):81. doi: 10.3390/ijms23010081. Int J Mol Sci. 2021. PMID: 35008514 Free PMC article.
-
Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.Cancer Res Commun. 2024 Aug 1;4(8):2282-2294. doi: 10.1158/2767-9764.CRC-24-0153. Cancer Res Commun. 2024. PMID: 39113608 Free PMC article.
-
Unveiling the role of KRAS in tumor immune microenvironment.Biomed Pharmacother. 2024 Feb;171:116058. doi: 10.1016/j.biopha.2023.116058. Epub 2024 Jan 2. Biomed Pharmacother. 2024. PMID: 38171240 Review.
Cited by
-
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nat Rev Clin Oncol. 2025 Jul;22(7):463-482. doi: 10.1038/s41571-025-01021-1. Epub 2025 May 16. Nat Rev Clin Oncol. 2025. PMID: 40379986 Free PMC article. Review.
References
-
- Smeltzer MP, Liao W, Faris NR, et al. Potential impact of criteria modifications on race and sex disparities in eligibility for lung cancer screening. J Thorac Oncol. 2023;18(2):158–168. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous